Corpus overview


Overview

MeSH Disease

Human Phenotype

Transmission

Seroprevalence
    displaying 1 - 10 records in total 19
    records per page




    SARS-CoV-2 Infection Reaches MESHD the Human Nervous System: How?

    Authors: Vladimir N. Uversky; Fatma Elrashdy; Abdullah Aljadawi; Syed Moasfar Ali; Rizwan Hasan Khan; Elrashdy M. Redwan

    id:10.20944/preprints202008.0696.v1 Date: 2020-08-31 Source: Preprints.org

    Without protective and/or therapeutic agents the SARS-CoV-2 infection MESHD known as coronavirus disease MESHD 2019 (COVID-19) is quickly spreading worldwide. It has surprising transmissibility TRANS potential, since it could infect MESHD all ages TRANS, gender TRANS, and human sectors. It attacks respiratory, gastrointestinal, urinary, hepatic, and endovascular systems and can reach the peripheral nervous system (PNS) and central nervous system (CNS) through known and unknown mechanisms. The reports on the neurological manifestations and complications of the SARS-CoV-2 infection MESHD are increasing exponentially. Herein, we enumerate seven candidate routes, which the mature or immature SARS-CoV-2 components could use to reach the CNS and PNS, utilizing the within-body crosstalk between organs. The majority of SARS-CoV-2 infected MESHD patients suffer from some neurological manifestations (e.g., confusion HP confusion MESHD, anosmia HP anosmia MESHD, and ageusia MESHD). It seems that although the mature virus did not reach the CNS or PNS of the majority of patients, its unassembled components and/or the accompanying immune-mediated responses may be responsible for the observed neurological symptoms. The viral particles and/or its components have been specifically documented in endothelial cells of lung, kidney, skin, and CNS. This means that the blood SERO-endothelial-barrier may be considered as the main route for SARS-CoV-2 entry into the nervous system, with the barrier disruption being more logical than barrier permeability, as evidenced by postmortem analyses.

    Outcome of Conservative Therapy in COVID-19 Patients Presenting with Gastrointestinal Bleeding

    Authors: DM Shalimar; Manas Vaishnav; Anshuman Elhence; Ramesh Kumar; Srikant Mohta; Chandan Palle; Peeyush Kumar; Mukesh Ranjan; Tanmay Vajpai; Shubham Prasad; Jatin Yegurla; Anugrah Dhooria; Vikas Banyal; Samagra Agarwal; Rajat Bansal; Sulagna Bhattacharjee; Richa Aggarwal; Kapil D Soni; Swetha Rudravaram; Ashutosh K Singh; Irfan Altaf; Avinash Choudekar; Soumya J Mahapatra; Deepak Gunjan; Saurabh Kedia; Govind Makharia; Anjan Trikha; Pramod Garg; Anoop Saraya

    doi:10.1101/2020.08.06.20169813 Date: 2020-08-07 Source: medRxiv

    Background: There is a paucity of data on the management of gastrointestinal(GI) bleeding MESHD in patients with COVID-19 amid concerns about the risk of transmission TRANS during endoscopic procedures.We aimed to study the outcomes of conservative treatment for GI bleeding MESHD in patients with COVID-19. Methods: In this retrospective analysis, 24 of 1342(1.8%) patients with COVID-19, presenting with GI bleeding MESHD from 22ndApril to 22ndJuly 2020, were included. Results: The mean age TRANS of patients was 45.8+/-12.7 years; 17(70.8%) were males TRANS; upper GI(UGI) bleeding MESHD: lower GI MESHD(LGI) 23:1. Twenty-two(91.6%) patients had evidence of cirrhosis HP cirrhosis MESHD- 21 presented with UGI bleeding MESHD while one had bleeding MESHD from hemorrhoids HP hemorrhoids MESHD. Two patients without cirrhosis HP cirrhosis MESHD were presumed to have non-variceal bleeding MESHD. The medical therapy for UGI bleeding included vasoconstrictors- somatostatin in 17(73.9%) and terlipressin in 4(17.4%) patients. All patients with UGI bleeding MESHD received proton pump inhibitors and antibiotics. Packed red blood SERO cells(PRBCs), fresh frozen plasma SERO and platelets were transfused in 14(60.9%), 3(13.0%) and 3(13.0%), respectively. The median PRBCs transfused was 1(0-3) unit(s). The initial control of UGI bleeding MESHD was achieved in all 23 patients and none required an emergency endoscopy. At 5-day follow-up, none rebled or died. Two patients later rebled, one had intermittent bleed due to gastric antral vascular ectasia MESHD, while another had rebleed 19 days after discharge. Three(12.5%) cirrhosis HP cirrhosis MESHD patients succumbed to acute hypoxemic respiratory failure MESHD respiratory failure HP during hospital stay. Conclusion: Conservative management strategies including pharmacotherapy, restrictive transfusion strategy, and close hemodynamic monitoring can successfully manage GI bleeding MESHD in COVID-19 patients and reduce need for urgent endoscopy.

    Seroprevalence SERO of COVID-19 in Niger State

    Authors: Hussaini Majiya; Mohammed Aliyu-Paiko; Vincent Tochukwu Balogu; Dickson Achimugu Musa; Ibrahim Maikudi Salihu; Abdullahi Abubakar Kawu; Ishaq Yakubu Bashir; Aishat Rabiu Sani; John Baba; Amina Tako Muhammad; Fatima Ladidi Jibril; Ezekiel Bala; Nuhu George Obaje; Yahaya Badeggi Aliyu; Ramatu Gogo Muhammad; Hadiza Mohammed; Usman Naji Gimba; Abduljaleel Uthman; Hadiza Muhammad Liman; Sule Alfa Alhaji; Joseph Kolo James; Muhammad Muhammad Makusidi; Mohammed Danasabe Isah; Ibrahim Abdullahi; Umar Ndagi; Bala Waziri; Chindo Ibrahim Bisallah; Naomi John Dadi-Mamud; Kolo Ibrahim; Abu Kasim Adamu

    doi:10.1101/2020.08.04.20168112 Date: 2020-08-05 Source: medRxiv

    Coronavirus Disease MESHD 2019 (COVID-19) Pandemic is ongoing, and to know how far the virus has spread in Niger State, Nigeria, a pilot study was carried out to determine the COVID-19 seroprevalence SERO, patterns, dynamics, and risk factors in the state. A cross sectional study design and clustered-stratified-Random sampling strategy were used. COVID-19 IgG and IgM Rapid Test SERO Kits (Colloidal gold immunochromatography lateral flow system) were used to determine the presence or absence of antibodies to SARS-CoV-2 SERO in the blood SERO of sampled participants across Niger State as from 26th June 2020 to 30th June 2020. The test kits were validated using the blood SERO samples of some of the NCDC confirmed positive and negative COVID-19 cases in the State. COVID-19 IgG and IgM Test results were entered into the EPIINFO questionnaire administered simultaneously with each test. EPIINFO was then used for both the descriptive and inferential statistical analyses of the data generated. The seroprevalence SERO of COVID-19 in Niger State was found to be 25.41% and 2.16% for the positive IgG and IgM respectively. Seroprevalence SERO among age groups TRANS, gender TRANS and by occupation varied widely. A seroprevalence SERO of 37.21% was recorded among health care workers in Niger State. Among age groups TRANS, COVID-19 seroprevalence SERO was found to be in order of 30-41 years (33.33%) > 42-53 years (32.42%) > 54-65 years (30%) > 66 years and above (25%) > 6-17 years (19.20%) > 18-29 years (17.65%) > 5 years and below (6.66%). A seroprevalence SERO of 27.18% was recorded for males TRANS and 23.17% for females TRANS in the state. COVID-19 asymptomatic TRANS rate in the state was found to be 46.81%. The risk analyses showed that the chances of infection MESHD are almost the same for both urban and rural dwellers in the state. However, health care workers and those that have had contact with person (s) that travelled TRANS out of Nigeria in the last six (6) months are twice ( 2 times) at risk of being infected with the virus. More than half (54.59%) of the participants in this study did not practice social distancing at any time since the pandemic started. Discussions about knowledge, practice and attitude of the participants are included. The observed Niger State COVID-19 seroprevalence SERO means that the herd immunity for COVID-19 is yet to be achieved and the population is still susceptible for more infection MESHD and transmission TRANS of the virus. If the prevalence SERO stays as reported here, the population will definitely need COVID-19 vaccines when they become available. Niger State should fully enforce the use of face/nose masks and observation of social/physical distancing in gatherings including religious gatherings in order to stop or slow the spread of the virus.

    Serial population based serosurvey of antibodies to SARS-CoV-2 SERO in a low and high transmission TRANS area of Karachi, Pakistan

    Authors: Muhammad Imran Nisar; Nadia Ansari; Mashal Amin; Farah Khalid; Aneeta Hotwani; Najeeb Rehman; Arjumand Rizvi; Arslan Memon; Zahoor Ahmed; Ashfaque Ahmed; Junaid Iqbal; Ali Faisal Saleem; Uzma Bashir Aamir; Daniel B Larremore; Bailey Fosdick; Fyezah Jehan

    doi:10.1101/2020.07.28.20163451 Date: 2020-07-29 Source: medRxiv

    Background Pakistan is among the first low- and middle-income countries affected by COVID-19 pandemic. Monitoring progress through serial sero-surveys SERO, particularly at household level, in densely populated urban communities can provide insights in areas where testing is non-uniform. Methods Two serial cross-sectional household surveys were performed in April (phase 1) and June (phase 2) 2020 each in a low- (District Malir) and high- transmission TRANS (District East) area of Karachi, Pakistan. Household were selected using simple random sampling (Malir) and systematic random sampling (East). Individual participation rate from consented households was 82.3% (1000/1215 eligible) in phase 1 and 76.5% (1004/1312 eligible) in phase 2. All household members or their legal guardians answered questions related to symptoms of Covid-19 and provided blood SERO for testing with commercial Elecsys Anti-SARS-CoV-2 immunoassay SERO targeting combined IgG and IgM. Seroprevalence SERO estimates were computed for each area and time point independently. Given correlation among household seropositivity values, a Bayesian regression model accounting for household membership, age TRANS and gender TRANS was used to estimate seroprevalence SERO. These estimates by age TRANS and gender TRANS were then post-stratified to adjust for the demographic makeup of the respective district. The household conditional risk of infection TRANS risk of infection TRANS was estimated for each district and its confidence interval were obtained using a non-parametric bootstrap of households. Findings Post-stratified seroprevalence SERO was estimated to be 0.2% (95% CI 0-0.7) in low-and 0.4% (95% CI 0 - 1.3) in high- transmission TRANS areas in phase 1 and 8.7% (95% CI 5.1-13.1) in low- and 15.1% (95% CI 9.4 -21.7) in high- transmission TRANS areas in phase 2, with no consistent patterns between prevalence SERO rates for males TRANS and females TRANS. Conditional risk of infection TRANS risk of infection TRANS infection MESHD estimates (possible only for phase 2) were 0.31 (95% CI 0.16-0.47) in low- and 0.41(95% CI 0.28-0.52) in high- transmission TRANS areas. Of the 166 participants who tested positive, only 9(5.4%) gave a history of any symptoms. Interpretation A large increase in seroprevalence SERO to SARS-CoV-2 infection MESHD is seen, even in areas where transmission TRANS is reported to be low. Mostly the population is still seronegative. A large majority of seropositives do not report any symptoms. The probability that an individual in a household is infected, given that another household member is infected is high in both the areas. These results emphasise the need to enhance surveillance activities of COVID-19 especially in low- transmission TRANS sites and provide insights to risks of household transmission TRANS in tightly knit neighbourhoods in urban LMIC settings.

    SARS-CoV-2 viral load dynamics, duration of viral shedding and infectiousness: a living systematic review and meta-analysis

    Authors: Muge Cevik; Matthew Tate; Oliver Lloyd; Alberto Enrico Maraolo; Jenna Schafers; Antonia Ho

    doi:10.1101/2020.07.25.20162107 Date: 2020-07-28 Source: medRxiv

    Background Viral load kinetics and the duration of viral shedding are important determinants for disease transmission TRANS. We aim i) to characterise viral load dynamics, duration of viral RNA, and viable virus shedding of SARS-CoV-2 in various body fluids and ii) to compare SARS-CoV-2 viral dynamics with SARS-CoV-1 and MERS-CoV. Methods: Medline, EMBASE, Europe PMC, preprint servers and grey literature were searched to retrieve all articles reporting viral dynamics and duration of SARS-CoV-2, SARS-CoV-1 and MERS-CoV shedding. We excluded case reports and case series with < 5 patients, or studies that did not report shedding duration from symptom onset TRANS. PROSPERO registration: CRD42020181914. Findings: Seventy-nine studies on SARS-CoV-2, 8 on SARS-CoV-1, and 11 on MERS-CoV were included. Mean SARS-CoV-2 RNA shedding duration in upper respiratory tract, lower respiratory tract, stool and serum SERO were 17.0, 14.6, 17.2 and 16.6 days, respectively. Maximum duration of SARS-CoV-2 RNA shedding reported in URT, LRT, stool and serum SERO was 83, 59, 35 and 60 days, respectively. Pooled mean duration of SARS-CoV-2 RNA shedding was positively associated with age TRANS (p=0.002), but not gender TRANS (p = 0.277). No study to date has detected live virus beyond day nine of illness despite persistently high viral loads. SARS-CoV-2 viral load in the upper respiratory tract appears to peak in the first week of illness, while SARS-CoV-1 and MERS-CoV peak later. Conclusion: Although SARS-CoV-2 RNA shedding in respiratory and stool can be prolonged, duration of viable virus is relatively short-lived. Thus, detection of viral RNA cannot be used to infer infectiousness. High SARS-CoV-2 titres are detectable in the first week of illness with an early peak observed at symptom onset TRANS to day 5 of illness. This review underscores the importance of early case finding and isolation, as well as public education on the spectrum of illness. However, given potential delays in the isolation of patients, effective containment of SARS-CoV-2 may be challenging even with an early detection and isolation strategy. Funding: No funding was received.

    Joint CBC-ICT Interpretation for the pre-surgical screening of COVID 19 asymptomatic TRANS cases: A cross-sectional study

    Authors: Tanzeel Imran; Humera Altaf Naz; Hamza Khan; Ali Haider Bangash; Laraib Bakhtiar Khan; Haroon Khan

    doi:10.1101/2020.07.16.20138354 Date: 2020-07-17 Source: medRxiv

    Background On 26th, February 2020, first cases of COVID 19 were confirmed in Pakistan. Since then, surgeries were halted in a bid to prevent transmission TRANS. However, since such a long halt is infeasible, a general protocol of screening the carriers TRANS, especially asymptomatic TRANS carries, is a dire need of time. The objective of our study is to propose an economically feasible protocol of COVID 19 screening. Simple but effective screening strategies can help to restore the workings of hospital surgical departments. Methods We analyzed the clinical data of patients turning up for elective surgeries at the Rawal General Hospital (RGH), Islamabad from the 24th of March to the 15th of May, 2020. Asymptomatic TRANS patients with negative COVID 19 contact and travel TRANS histories were screened with COVID 19 Immunochromatography (ICT) IgM / IgG Ab Test. Complete blood SERO count (CBC) was done and interpreted in conjunction with the ICT results. Results 39 patients with a mean age TRANS of 49 years were studied. The result of ICT for COVID-19 was positive in 9 cases (23%). The entire positive ICT patients population expressed significantly lower lymphocyte count (p<0.01); 8 patients had high monocyte count (p<0.05) whereas only 4 patients had a combined high neutrophil and monocyte count (P<0.05). All of these four patients with high neutrophil count were females TRANS. The combined interpretation of CBC and ICT IgM / IgG Ab Test had a high accuracy in diagnosing asymptomatic TRANS COVID-19 carriers TRANS that were later confirmed by real-time reverse transcriptase-polymerase chain reaction (rRT-PCR). Conclusion We propose that joint CBC-ICT interpretation should be adopted on a large scale to help in the diagnoses of asymptomatic TRANS carriers TRANS as both tests are simple and inexpensive and thus suit the developing countries limited health budget. Future research projects should be adopted in order to assess the accuracy of the proposed protocol on a large scale. Keywords: COVID-19, Surgery, Asymptomatic TRANS carriers TRANS, ICT, CBC.

    Clinical utility of targeted SARS-CoV-2 serology testing to aid the diagnosis and management of suspected missed, late or post-COVID-19 infection syndromes: results from a pilot service

    Authors: Nicola Sweeney; Blair Merrick; Suzanne Pickering; Rui Pedro Galao; Alina Botgros; Harry D. Wilson; Adrian W. Signell; Gilberto Betancor; Mark Kia Ik Tan; John Ramble; Neophytos Kouphou; Sam Acors; Carl Graham; Jeffrey Seow; Eithne MacMahon; Stuart J. D. Neil; Michael H. Malim; Katie Doores; Sam Douthwaite; Rahul Batra; Gaia Nebbia; Jonathan D. Edgeworth

    doi:10.1101/2020.07.10.20150540 Date: 2020-07-11 Source: medRxiv

    Objectives: Determine indications and clinical utility of SARS-CoV-2 serology testing in adults TRANS and children TRANS. Design: Prospective evaluation of initial three weeks of a daily Monday to Friday pilot SARS-CoV-2 serology service for patients. Setting: Early post 'first-wave' SARS-CoV-2 transmission TRANS period at single centre London teaching hospital that provides care to the local community, as well as regional and national referral pathways for specialist services. Participants: 110 (72 adults TRANS, 38 children TRANS, age TRANS range 0-83 years, 52.7% female TRANS (n=58)). Interventions: Patient serum SERO from vetted referrals tested on CE marked and internally validated lateral flow immunoassay SERO (LFIA) (SureScreen Diagnostics) detecting antibodies to SARS-CoV-2 SERO spike proteins, with result and clinical interpretation provided to the direct care team. Main outcome measures: Performance SERO characteristics, source and nature of referrals, feasibility and clinical utility of the service, particularly the benefit for clinical decision-making. Results: The LFIA was deemed suitable for clinical advice and decision making following evaluation with 310 serum samples SERO from SARS-CoV-2 PCR positive patients and 300 pre-pandemic samples, giving a sensitivity SERO and specificity of 96.1% and 99.3% respectively. For the pilot, 115 referrals were received leading to 113 tests performed on 108 participants (sample not available for two participants); paediatrics (n=35), medicine (n=69), surgery (n=2) and general practice (n=2). 43.4% participants (n=49) had detectable antibodies to SARS-CoV-2 SERO. There were three main indications for serology; new acute presentations potentially triggered by recent COVID-19 infection e.g. PIMS-TS (n=26) and pulmonary embolism HP pulmonary embolism MESHD (n=5), potential missed diagnoses in context of a recent compatible illness (n=40), and making infection control and immunosuppression treatment decisions in persistently SARS-CoV-2 RNA PCR positive individuals (n=6). Conclusions: This study shows acceptable performance SERO characteristics, feasibility and clinical utility of a SARS-CoV-2 serology service using a rapid, inexpensive and portable assay for adults TRANS and children TRANS presenting with a range of clinical indications. Results correlated closely with a confirmatory in-house ELISA SERO. The study showed the benefit of introducing a serology service where there is a reasonable pre-test probability, and the result can be linked with clinical advice or intervention. Experience thus far is that the volume of requests from hospital referral routes are manageable within existing clinical and laboratory services; however, the demand from community referrals has not yet been assessed. Given recent evidence for a rapid decline in antibodies SERO, particularly following mild infection MESHD, there is likely a limited window of opportunity to realise the benefit of serology testing for individuals infected during the 'first-wave' before they potentially fall HP below a measurable threshold. Rapidly expanding availability of serology services for NHS patients will also help understand the long-term implications of serostatus and prior infection MESHD in different patient groups, particularly before emergence of any 'second-wave' outbreak or introduction of a vaccination programme.

    SARS-CoV-2 Seroprevalence SERO Rates of Children TRANS in Louisiana During the State Stay at Home Order.

    Authors: Monika L Dietrich; Elizabeth B Norton; Debra Elliott; Ashley R Smira; Julie A Rouelle; Nell G Bond; Karen Aime-Marcelin; Alisha Prystowsky; Rebecca Kemnitz; Arunava Sarma; Sarah Talia Himmelfarb; Neha Sharma; Addison E Stone; Randall Craver; Alyssa R Lindrose; Leslie A Smitley; Robert B Uddo; Leann Myers; Stacy S Drury; John S Schieffelin; James E Robinson; Kevin J Zwezdaryk

    doi:10.1101/2020.07.07.20147884 Date: 2020-07-08 Source: medRxiv

    Children TRANS (less than 19 years) account for 20% of the US population but currently represent less than 2% of coronavirus disease MESHD 2019 (COVID-19) cases. Because infected children TRANS often have few or no symptoms and may not be tested, the extent of infection in children TRANS is poorly understood. METHODS During the March 18th-May 15th 2020 Louisiana Stay At Home Order, 1690 blood SERO samples from 812 individuals from a Childrens Hospital were tested for antibodies SERO to severe acute respiratory syndrome coronavirus 2 MESHD (SARS-CoV-2) spike protein. Demographics, COVID-19 testing, and clinical presentation abstracted from medical records were compared with local COVID-19 cases. RESULTS In total, 62 subjects (7.6%) were found to be seropositive. The median age TRANS was 11 years with 50.4% female TRANS. The presenting complaint of seropositive patients was chronic illness MESHD (43.5%). Only 18.2% had a previous positive COVID-19 PCR or antibody test SERO. Seropositivity was significantly associated with parish (counties), race, and residence in a low-income area. Importantly, seropositivity was linearly correlated with cumulative COVID-19 case number for all ages TRANS by parish. CONCLUSION In a large retrospective study, the seropositivity prevalence SERO for SARS-CoV-2 in children TRANS in Louisiana during the mandated Stay At Home Order was 7.6%. Residence location, race, and lower socioeconomic factors were linked to more frequent seropositivity in children TRANS and correlated to regional COVID-19 case rates. Thus, a significant number of children TRANS in Louisiana had SARS-CoV-2 infections MESHD that went undetected and unreported and may have contributed to virus transmission TRANS.

    Severe COVID-19 in cardiopath young pregnant without vertical transmission TRANS: a case report

    Authors: Ana Paula Figueiredo de Montalvão França; Danielly do Vale Pereira; Elaine Valéria Rodrigues; Flávia Nunes Vieira; Karine Santos Machado; Pedro Aleixo Nogueira; Ricardo Roberto de Souza Fonseca; Luiz Fernando Almeida Machado

    doi:10.21203/rs.3.rs-40095/v1 Date: 2020-07-03 Source: ResearchSquare

    Background: The new betacoronavirus known as severe acute respiratory syndrome coronavirus 2 MESHD (SARS-CoV-2) is the cause of COVID-19, and has spread rapidly around the world, reaching more than 200 countries, around 7 million people and causing more than 400.000 deaths according to the World Health Organization. Case presentation: A 26-year-old female TRANS at 28 weeks of gestation with regular prenatal care, a heart disease MESHD condition and no previous history of recent national or international traveling presented to a cardiology hospital, in Northern Brazil, with dry cough MESHD cough HP, sustained/continuous high fever HP, which quickly evolved to respiratory failure HP respiratory failure MESHD. Once stabilized an emergency cesarean was performed to preserve the fetus life. After surgery both patient and newborn were in Intensive Care Unit, then both patient and newborn nasopharyngeal and oropharyngeal secretion were obtained to test for respiratory viral infections MESHD, such as SARS-CoV-2, also blood SERO samples were collected for laboratory exams. The patient’s tested positive for SARS-CoV-2 however her newborn SARS-CoV-2. And during treatment due patient’s conditions and severity the case evolved to death.Conclusion: This report highlights the relevance of comorbidities for the unfavorable clinical course of COVID-19, despite the adequate treatment used for patients affected by COVID-19, especially among the risk groups, as well as demonstrating the absence of vertical transmission TRANS of SARS-CoV-2. 

    Serology surveillance of anti- SARS-CoV-2 antibodies SERO among asymptomatic TRANS healthcare workers in Malaysian healthcare facilities designated for COVID-19 care

    Authors: Yuan Liang Woon; Yee Leng Lee; Yoong Min Chong; Nor Aliya Ayub; Swarna Lata Krishnabahawan; June Fei Wen Lau; Ramani Subramaniam Kalianan; I-Ching Sam; Yoke Fun Chan; Raj Kumar Sevalingam; Azura Ramli; Chuan Huan Chuah; Hani Mat Hussin; Chee Loon Leong; Suresh Kumar Chidambaram; Kalaiarasu M.Peariasamy; Pik Pin Goh

    doi:10.21203/rs.3.rs-37132/v1 Date: 2020-06-20 Source: ResearchSquare

    IntroductionHealthcare workers (HCW) are presumed to be at increased risk of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection MESHD due to occupational exposure to infected MESHD patients. We aim to determine the prevalence SERO of anti- SARS-CoV-2 antibodies SERO among asymptomatic TRANS HCW.MethodsWe prospectively recruited HCW from the National Public Health Laboratory and two COVID-19 designated public hospitals in Klang Valley, Malaysia between April 13th and May 12th, 2020. Quota sampling was applied to ensure adequate representation of the HCW involved in provision of care for patients directly and indirectly. All participants had worked in the respective healthcare facility for at least 30 days prior study enrollment. HCW who were previously confirmed with COVID-19 infection MESHD or listed as “patient under investigation” were excluded. A self-administered questionnaire was used to capture sociodemographic information, history of contact with COVID-19 cases within the past month, clinical signs and symptoms and adherence to universal precautions. Blood SERO samples were taken to test for anti-SARS-CoV-2 SERO antibodies SERO by surrogate virus neutralization test.ResultsA total of 400 HCW were recruited, comprising 154 (38.5%) nurses, 103 (25.8%) medical doctors, 47 (11.8%) laboratory technologists and others (23.9%). The mean age TRANS was 35±7.8 years, with females TRANS predominant (74%). A majority (68.9%) reported direct contact with COVID-19 patients, body fluids of COVID-19 patients and/or contaminated objects and surfaces in the past month within their respective workplaces. Nearly all claimed to adhere to personal protection equipment (PPE) guidelines (97%-100% adherence) and hand hygiene practice (91%-96% adherence). None (95% CI: 0, 0.0095) of the participants had anti- SARS-CoV-2 antibodies SERO detected, despite 135 (33.8%) reporting respiratory symptoms one month prior to study recruitment. One hundred and fifteen (29%) participants claimed to have contact with known COVID-19 persons outside of the workplace.ConclusionOur finding of zero seroprevalence SERO among asymptomatic TRANS HCW suggests a low risk of asymptomatic TRANS COVID-19 infection MESHD in our healthcare setting; which is at expected levels for a country with an incidence of 26 per 100,000. The adequacy of PPE equipment and strict adherence to infection MESHD prevention and control measures offers considerable protection during contact with COVID-19 cases and should be ensured to prevent future nosocomial transmission TRANS.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.

Sources


Annotations

All
None
MeSH Disease
Human Phenotype
Transmission
Seroprevalence


Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.